Cyteir Therapeutics's EPS (Basic) for the
three
months ended in Sep. 2023 was $-0.10.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.94.
During the past 3 years, the average EPS without NRIGrowth Rate was -19.20% per year.
During the past 4 years, Cyteir Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -19.20% per year. The lowest was -19.20% per year. And the median was -19.20% per year.
Cyteir Therapeutics Earnings per Share (Diluted) Historical Data
The historical data trend for Cyteir Therapeutics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cyteir Therapeutics Earnings per Share (Diluted) Chart
Competitive Comparison of Cyteir Therapeutics's Earnings per Share (Diluted)
For the Biotechnology subindustry, Cyteir Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's PE Ratio falls into.
Cyteir Therapeutics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Cyteir Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Cyteir Therapeutics (OTCPK:CYTT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Cyteir Therapeutics Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Cyteir Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your 